· Published by Health Canada · Official notice
This is duplicated text of a letter from GlaxoSmithKline Inc. Contact the company for a copy of any references, attachments or enclosures.
April 24, 2013
Subject: Updated Information – Potential for Glass-Related Particles in prFLOLAN® (epoprostenol sodium) Sterile Diluent and the Essential Use of a Filter with the Administration of the Reconstituted Product
(FLOLAN® 0.5 mg vial, DIN: 02230845; FLOLAN® 1.5 mg vial, DIN: 02230848; Sterile Diluent DIN: 02230857)
GlaxoSmithKline Inc., in consultation with Health Canada, is providing Canadians with updated information on the use of the pulmonary hypertension drug, FLOLAN®. Some vials of Sterile Diluent for FLOLAN® have been found to contain glass-related particles that may not be easily visible under normal lighting conditions. Studies indicate filtration through a 0.22 or 0.2 micron pore size filter is an effective means to remove these glass-related particles. The infusion tubing supplied by your Pharmaprix/Shoppers Drug Mart Specialty Pharmacy already incorporates a 0.2 micron filter.
There have been no reports of adverse events that could be definitively attributed to these glass-related particles in GlaxoSmithKline’s safety database for FLOLAN®.
Based on this information, GlaxoSmithKline would like to advise you of the following:
GlaxoSmithKline has sent a letter to healthcare professionals informing them of this safety information. A copy of that letter will be available on the Health Canada Website.
GlaxoSmithKline continues to search for improvements in the manufacturing process of the Sterile Diluent for FLOLAN® so that no vials will contain glass particles. Since the continued availability of this product is medically necessary for patients who require FLOLAN®, the use of a filter with the administration is essential for these patients.
For media inquiries, please contact GlaxoSmithKline Communications at (905) 819-3363.
Managing marketed health product-related side effects depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing side effects are generally presumed to underestimate the risks associated with health product treatments. Any serious or unexpected side effects in patients receiving FLOLAN® should be reported to GlaxoSmithKline Inc. or Health Canada.
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
Phone: 1-800-387-7374
You can report any suspected adverse reactions associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, please contact Health Canada at:
Health Products and Food Branch Inspectorate
E-mail: DCVIU_UVECM@hc-sc.gc.ca
Telephone: 1-800-267-9675
Fax: 1-613-946-5636
Sincerely,
Original signed by
Dr. Glenn Crater,
Vice President, Medical and Chief Medical Officer
GlaxoSmithKline Inc.
®FLOLAN is a registered trademark used under license by GlaxoSmithKline Inc.